Author:
Perez Matthew C.,Tanabe Kenneth K.,Ariyan Charlotte E.,Miura John T.,Mutabdzic Dorotea,Farma Jeffrey M.,Zager Jonathan S.
Publisher
Springer International Publishing
Reference149 articles.
1. Abdel-Wahab OI, Grubbs E, Viglianti BL, Cheng TY, Ueno T, Ko S, Rabbani Z, Curtis S, Pruitt SK, Dewhirst MW, Tyler DS (2004) The role of hyperthermia in regional alkylating agent chemotherapy. Clin Cancer Res 10:5919–5929
2. Agarwala SS, Neuberg D, Park Y, Kirkwood JM (2004) Mature results of a phase III randomized trial of bacillus Calmette-Guerin (BCG) versus observation and BCG plus dacarbazine versus BCG in the adjuvant therapy of American Joint Committee on Cancer Stage I-III melanoma (E1673): a trial of the Eastern Oncology Group. Cancer 100:1692–1698
3. Amaria RN, Prieto PA, Tetzlaff MT, Reuben A, Andrews MC, Ross MI, Glitza IC, Cormier J, Hwu WJ, Tawbi HA, Patel SP, Lee JE, Gershenwald JE, Spencer CN, Gopalakrishnan V, Bassett R, Simpson L, Mouton R, Hudgens CW, Zhao L, Zhu H, Cooper ZA, Wani K, Lazar A, Hwu P, Diab A, Wong MK, Mcquade JL, Royal R, Lucci A, Burton EM, Reddy S, Sharma P, Allison J, Futreal PA, Woodman SE, Davies MA, Wargo JA (2018) Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. Lancet Oncol 19:181–193
4. Andtbacka RHI, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, Delman KA, Spitler LE, Puzanov I, Agarwala SS, Milhem M, Cranmer L, Curti B, Lewis K, Ross M, Guthrie T, Linette GP, Daniels GA, Harrington K, Middleton MR, Miller WH, Zager JS, Ye YN, Yao B, Li A, Doleman S, Vanderwalde A, Gansert J, Coffin RS (2015) Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. J Clin Oncol 33:2780–2U98
5. Andtbacka RHI, Curti B, Hallmeyer S, Fox B, Feng Z, Paustian C, Bifulco C, Grose M, Shafren DR (2016) Phase II CALM extension study: intratumoral CAVATAK increases immune-cell infiltrates and up-regulates immune-checkpoint molecules in the microenvironment of lesions from advanced melanoma patients. J Immunother Cancer 4:319